A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

References

• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–12. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327–37. doi:10.1084/jem.176.2.327.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96. doi:10.1111/imr.12519.
   PubMed Web of Science ®Google Scholar
• Zahm CD, Moseman JE, Delmastro LE, M DG. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. Oncoimmunology. 2021;10(1):1912892. doi:10.1080/2162402x.2021.1912892.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620–2627. doi:10.1200/jco.19.02727.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi:10.1038/s41571-021-00473-5.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383–3392. doi:10.1172/jci31184.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. doi:10.1158/0008-5472.Can-11-1620.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMoa2109970.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Tan DSW, Martín M, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10(2):e003776. doi:10.1136/jitc-2021-003776.
   PubMed Web of Science ®Google Scholar
• Naing A, Gainor JF, Gelderblom H, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020;8(1):e000530. doi:10.1136/jitc-2020-000530.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Sci. 2018;362(6411). doi:10.1126/science.aar3593
   PubMed Web of Science ®Google Scholar
• Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–1540. doi:10.1016/s1470-2045(21)00471-x.
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. doi:10.1016/s0140-6736(20)32714-8.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee H-G, Gouttefangeas C. PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunol Res. 2019;7(11):1891–9. doi:10.1158/2326-6066.Cir-19-0146.
   PubMed Web of Science ®Google Scholar
• Hamid O, Wang D, Kim TM, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15_suppl):9515–. doi:10.1200/JCO.2021.39.15_suppl.9515.
   Web of Science ®Google Scholar
• Long GV, Hodi FS, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). J Clin Oncol. 2022;40(36_suppl):360385–. doi:10.1200/JCO.2022.40.36_suppl.360385.
   Web of Science ®Google Scholar
• Ascierto PA, Bono P, Bhatia S, et al. LBA18 - efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann Oncol. 2017;28:v611–v2. doi:10.1093/annonc/mdx440.011.
   PubMed Web of Science ®Google Scholar
• Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–3353. doi:10.1002/cncr.30258.
   PubMed Web of Science ®Google Scholar
• Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016;5(5):e1143997. doi:10.1080/2162402x.2016.1143997.
   PubMed Web of Science ®Google Scholar
• Jindal V. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma. Chin Clin Oncol. 2018;7(1):8. doi:10.21037/cco.2018.01.05.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226–235. doi:10.1200/jco.2016.67.9258.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lee SJ, Chmielowski B, et al. Dreamseq (Doublet, randomized Evaluation in advanced melanoma sequencing): a phase III trial—ECOG-ACRIN EA6134. J Clin Oncol. 2021;39(36_suppl):356154–. doi:10.1200/JCO.2021.39.36_suppl.356154.
   Web of Science ®Google Scholar
• Gutierrez M, Lam W-S, Hellmann M, et al. 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC). J Immunother Cancer. 2021;9(Suppl 2):A485–A. doi:10.1136/jitc-2021-SITC2021.457.
   Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. doi:10.1093/annonc/mdy517.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast Cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82. doi:10.1001/jamaoncol.2018.4224.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi:10.1016/s1470-2045(19)30689-8.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/s0140-6736(20)32531-9.
   PubMed Web of Science ®Google Scholar
• Hernández-Camarero P, López-Ruiz E, Marchal JA, Perán M. Cancer: a mirrored room between tumor bulk and tumor microenvironment. J Exp Clin Cancer Res. 2021;40(1):217. doi:10.1186/s13046-021-02022-5.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40. doi:10.1172/jci91190.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–27. doi:10.1200/jco.2018.78.2276.
   PubMed Web of Science ®Google Scholar
• Thoracic Cancer: 2022 ASCO annual meeting highlights for the advanced practitioner. J Adv Pract Oncol. 2022;13(6):579–85. doi:10.6004/jadpro.2022.13.6.3.
   PubMedGoogle Scholar